← 返回

CAR 信号校准促进不对称细胞分裂以决定 CAR-T 细胞命运与抗肿瘤效力

英文原题:Calibration of CAR signaling promotes asymmetric cell division to direct CAR-T cell fate and antitumor potency.

查看英文原题

Calibration of CAR signaling promotes asymmetric cell division to direct CAR-T cell fate and antitumor potency.

PubMed 2026/08/14(内容时间) Cell Rep Q1 · IF 7.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

不对称细胞分裂(ACD)是一种在进化上保守的机制,可导致T细胞命运多样化,然而工程化受体信号如何在嵌合抗原受体(CAR)-T细胞中调控ACD仍不清楚。在此,我们表明抗原结合通过CAR免疫突触(CARIS)的极化继承诱导CAR-T 细胞发生ACD,支持产生具有不同功能轨迹的子代细胞。CAR高表达子代获得短寿命效应样状态,而CAR低表达子代保留记忆样特征,具有更强的持久性和更优的抗肿瘤疗效。我们确定CAR信号强度是这种命运分化的可调控决定因素:选择性突变CD3免疫受体酪氨酸激活基序(1XX CAR)可增强ACD。在机制上,1XX信号通过PLC 1-甘油二酯(DAG)极性轴促进分裂前MTOC-CARIS偶联,从而实现CARIS的不对称继承。过继转移研究进一步支持信号驱动的不对称性、命运决定与治疗疗效之间的联系。总之,我们的发现揭示CAR信号是通过突触偶联的不对称分裂调控命运多样化的调节因子。

展开英文摘要原文

Asymmetric cell division (ACD) is an evolutionarily conserved mechanism that diversifies T cell fate, yet how engineered receptor signaling regulates ACD in chimeric antigen receptor (CAR)-T cells remains unknown.

Here, we show that antigen engagement induces ACD in CAR-T cells through polarized inheritance of the CAR immune synapse (CARIS), supporting the generation of progeny with divergent functional trajectories. CAR high progeny acquires a short-lived effector-like state, whereas CAR low progeny retains memory-like features, with enhanced persistence and superior antitumor efficacy.

We identify CAR signaling strength as a tunable determinant of this fate bifurcation: selective mutation of CD3 immunoreceptor tyrosine-based activation motifs (1XX CAR) enhances ACD.

Mechanistically, 1XX signaling promotes pre-mitotic MTOC-CARIS coupling through the PLC 1-diacylglycerol (DAG) polarity axis, enabling asymmetric CARIS inheritance. Adoptive transfer studies further support a link between signaling-driven asymmetry, fate-determination, and therapeutic efficacy.

Together, our findings reveal CAR signaling as a regulator of fate diversification through synapse-coupled asymmetric division.

论文信息

作者
Shen X、Xu X、Jiang J、Zhang S、Chen J、Chen R、Gu Y、Zhou C
第一作者单位
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, 1369 West Wenyi Road, Hangzhou 311121, China; Department of Cell Biology, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou 310058, China.China
通讯作者单位
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, 1369 West Wenyi Road, Hangzhou 311121, China; Department of Cell Biology, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou 310058, China; Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310058, China. Electronic address: sunj4@zju.edu.cn.China
期刊
Cell reports2026 Aug 14
原文标识
PubMed 42603278 · DOI 10.1016/j.celrep.2026.117848